CytomX Therapeutics Reports Third Quarter 2023 Financial

- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1 dose escalation data anticipated in the first half of 2024 - - CX-2051 (EpCAM-directed ADC)...

Related Keywords

United States ,Stephanie Ascher ,Chris Ogden ,Marcia Belvin ,Sean Mccarthy ,Company Probody ,Society For Immunotherapy ,Bristol Myers Squibb ,Development Day ,Company Annual Report On Form ,Linkedin ,Cytomx Therapeutics Inc ,Twitter ,Amgen ,Company Priorities ,Nasdaq ,Bristol Myers Squibb Research ,Annual World ,Quarter Business Highlights ,Cytomx Therapeutics ,Annual Meeting ,Potential Milestones ,Probody Platform ,Quarterly Report ,Media Contact ,Myers Squibb Research ,Annual Report ,Nasdaq Ctmx ,Ytomx Therapeutics Inc ,